DarioHealth Corp. (DRIO) 股票分析

公司概述

DarioHealth Corp. operates as a digital health entity serving both domestic and international markets, utilizing a digital therapeutics platform and comprehensive solution suite to deliver personalized, data-driven interventions supported by individual coaching for conditions including diabetes, hypertension, weight management, and musculoskeletal issues. The company is categorized within the Healthcare sector, specifically under the Health Information Services industry, positioning it at the intersection of medical technology and patient management services. In terms of scale, the company currently holds a market capitalization of $51.83M with an annual revenue (TTM) of $22.36M and employs approximately 160 individuals. These valuation and revenue figures indicate that DarioHealth is a micro-cap entity operating with a relatively small balance sheet, suggesting it is in an early-stage growth or consolidation phase where operational efficiency and customer acquisition costs are critical determinants of future scalability.

财务健康

The company reported a revenue of $22.36M over the trailing twelve months, yet this generated a net income of $-40,309,576 and an EBITDA of $-33,517,000, revealing a significant structural cost burden where operating expenses and interest costs vastly exceed gross profits. The free cash flow stands at $-11,204,875, indicating that the company is burning cash to fund operations and growth initiatives, which limits its immediate financial flexibility without external capital injection. Analysis of the three key margins shows a gross margin of 64.1%, which suggests strong pricing power or low cost of goods relative to revenue, contrasted sharply by an operating margin of -163.7% and a profit margin of -186.6%, both of which reflect deep structural losses likely driven by high administrative, sales, or technology development costs. Regarding liquidity and leverage, the company holds $26.02M in cash against $31.75M in debt, resulting in a debt-to-equity ratio of 46.74, which signifies a highly leveraged balance sheet where interest obligations consume a substantial portion of earnings. The current ratio is recorded at 3.76, indicating that the company possesses 3.76 times the current assets needed to cover its short-term liabilities, suggesting adequate short-term liquidity despite the negative earnings. Furthermore, the return on equity is -59.6% and the return on assets is -20.0%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns, a common characteristic for companies in high-growth digital health sectors that have not yet achieved profitability.

估值评估

The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -16.32, implying that the market is pricing in future earnings recovery but currently valuing the stock based on non-traditional multiples. The price-to-book ratio is 0.72, indicating that the market is valuing the company at a discount to its book value, which often signals a market perception of underlying asset undervaluation or concerns regarding the quality and realizability of intangible assets. Alternative valuation metrics include a price-to-sales ratio of 2.32 and an EV/EBITDA of -1.72, suggesting that investors are willing to pay a premium relative to sales despite the lack of current profitability, likely betting on the scalability of the digital health platform. The stock has traded within a 52-week range with a high of $17.74 and a low of $5.93; without a specific current price provided in the facts, the valuation context is defined by this volatility band where the forward P/E of -16.32 suggests significant expected earnings improvement is required to justify the current market price. The beta value is 1.28, meaning the stock exhibits 28% higher volatility than the broader market, reflecting the heightened risk premium associated with small-cap biotech or digital health companies that are sensitive to interest rate changes and regulatory developments in the healthcare sector.

Growth & Income

The company experienced a revenue growth (YoY) of -31.2% and an earnings growth (YoY) that is N/A due to negative earnings history, indicating that the business is currently contracting rather than expanding in terms of top-line revenue. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests any available cash flow—or in this case, raises capital—to fund operations rather than distributing income to shareholders. The negative revenue growth combined with negative free cash flow suggests that the company is facing headwinds in customer retention or market penetration that are currently outweighing its digital platform capabilities. Overall, the growth and income profile is characterized by contraction in revenue and a complete reliance on external financing to sustain operations, as the company lacks both positive earnings growth and a mechanism to return capital to investors through dividends.